KRAS and small intestine neoplasm: We examine whether KYA1797K effectively inhibit the stemness of CSCs in small intestinal tumors of ApcMin/+/KrasG12DLA2 mice that exhibit synergistic activation of CSCs by Apc and Kras mutations (Additional file 1: Figure S4) [15, 16], we tested the effects of KYA1797K on the stemness of small intestinal tumors in ApcMin/+/KrasG12DLA2 mice.